ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones

Wednesday, April 2, 2008 General News J E 4
FREDERICK, Md., April 1, 2008 ImQuest BioSciences, Inc.announced today the publication of the results of an important structure-activity relationship study to investigate the efficacy and toxicity of aseries of pyrimidinedione analogs against HIV-1 and HIV-2. The manuscript,published in the journal Antiviral Chemistry and Chemotherapy, shows theresults of ImQuest's HIV drug development program based on compounds which itlicensed from Samjin Pharmaceutical Co. Ltd. The report, authored by Robert W.Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer ofImQuest) describes the synthesis of the highly potent pyrimidinedione seriesand the structural features of the compounds which are responsible for theirhigh level of potency against HIV, the expanded range of action to includeHIV-2, and the unique dual mechanism of entry and RT inhibitory activityagainst HIV-1.

"The studies performed will allow us to focus our resources on thepreclinical and clinical development of the most potent lead pyrimidinedioneand to gain insight into the molecular features of the compounds which yieldthe high potency and characteristic dual mechanism of antiviral action ofthese unique compounds," explained Dr. Buckheit. Other coauthors on this paperinclude ImQuest virologists Tracy Hartman, Karen Watson and Lu Yang and Samjinchemists Ho-Seok Kwon, Sun-Hwan Lee, Jae-Woong Lee, Dong-Wook Kang, Sun-GanChung and Eui-Hwan Cho.

ImQuest expects to submit an IND to initiate Phase 1 human clinical trialswith IQP-0410, a highly potent member of the pyrimidinedione series in thethird quarter of 2008. In addition, ImQuest has initiated IND-enabling studieswith the pyrimidinedione IQP-0528 as a potential anti-HIV topical microbicide.

ImQuest Life Sciences, a privately held U.S. company located in Frederick,Maryland specializes in early stage drug development of novel compounds forthe treatment of infectious disease and cancer. Samjin Pharmaceutical Co., apublicly held company listed on the Korean Stock Exchange, is one of theleading pharmaceutical companies in Korea. ImQuest BioSciences, also locatedin Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology andpharmaceutical industry.For further information regarding this press release please contact: Robert W. Buckheit, Jr., Ph.D. Executive Vice President and Chief Scientific Officer ImQuest Life Sciences, Inc. 301-696-0274

SOURCE ImQuest BioSciences, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
IHPM and HealthMedia Announce Industry's First Beh...
AEterna Zentaris and Paladin Labs Complete Sale an...